[Paper-level Aggregated]
PMCID: PMC3100313
Evidence Type(s): Oncogenic, Predictive, Functional
Justification:
Oncogenic: The presence of the IDH1 R132H mutation is associated with glioblastoma and is implicated in tumorigenesis through the alteration of normal enzyme function and the accumulation of oncometabolites like D-2-hydroxyglutarate.
Predictive: The identification of the IDH1 R132H mutation in glioblastomas suggests that it may serve as a predictive biomarker for the presence of this specific mutation in tumor samples, which could influence treatment decisions.
Functional: The mutation at codon 132 (R132H) results in a gain-of-function change that alters the enzymatic activity of IDH1, leading to the production of D-2-hydroxyglutarate, which is relevant to the functional consequences of the mutation in the context of glioblastoma.
Gene→Variant (gene-first):
D2HGDH(728294):R132
L2HGDH(79944):arginine to histidine
D2HGDH(728294):c.395G>A
IDH1(3417):p.R132H
IDH1(3417):R132H
Genes:
D2HGDH(728294)
L2HGDH(79944)
IDH1(3417)
Variants:
R132
arginine to histidine
c.395G>A
p.R132H
R132H